RNA
$13.77
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
Intraday
Recent News
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal
Seven-tranche bond sale helps repay bridge loan tied to Avidity acquisition, amid $26 billion investment-grade issuance surge.
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger
Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 23, Avidity Biosciences Inc. (NASDAQ:RNA) adjourned its special stockholder meeting scheduled for the same day and moved the date to February 26. Avidity Biosciences Inc. (NASDAQ:RNA) […]
European Stocks Mostly Higher in Friday Trading; French GDP Growth Slows, Inflation Rises
The European stock markets were mostly higher in Friday trading as The Stoxx Europe gained 0.2%, Ger
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
Four months after Avidity’s $12 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its predecessor’s work in cardiovascular disease.